AN2 Therapeutics (ANTX) Liabilities and Shareholders Equity (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Liabilities and Shareholders Equity data on file, last reported at $87.5 million in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $87.5 million, up 7.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $292.5 million (down 22.94% YoY), and the FY2025 annual result was $62.0 million, down 32.73% from the prior year.
• Liabilities and Shareholders Equity climbed to $87.5 million in Q1 2026 per ANTX's latest filing, from $62.0 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $153.8 million in Q3 2023 and troughed at $62.0 million in Q4 2025.
• A 5-year average of $101.7 million and a median of $98.9 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity jumped 57.02% in 2022, then tumbled 36.49% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $102.6 million in 2022, then surged by 35.28% to $138.7 million in 2023, then tumbled by 33.63% to $92.1 million in 2024, then plunged by 32.73% to $62.0 million in 2025, then jumped by 41.23% to $87.5 million in 2026.
• Business Quant data shows ANTX's Liabilities and Shareholders Equity at $87.5 million in Q1 2026, $62.0 million in Q4 2025, and $67.2 million in Q3 2025.